公开(公告)号：WO2012045195A1

公开(公告)日：2012-04-12

申请号：PCT/CN2010/001578

申请日：2010-10-09

Applicant: ABBOTT LABORATORIES ,  ABBOTT LABORATORIES TRADING (SHANGHAI) COMPANY, LTD. ,  VAN CAMP, Jennifer ,  XU, Xiangdong ,  OSUMA, Augustine, Toby ,  GREGG, Robert ,  LONGENECKER, Kenton, L.

Inventor： VAN CAMP, Jennifer ,  XU, Xiangdong ,  OSUMA, Augustine, Toby ,  GREGG, Robert ,  LONGENECKER, Kenton, L.

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/04

Abstract: Disclosed are compounds which inhibit the activity of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK), compositions containing the compounds, and methods of treating diseases during which FAK and ALK are expressed. The diseases are, for example, cancers.

Abstract translation: 公开了抑制粘着斑激酶（FAK）和间变性淋巴瘤激酶（ALK）活性的化合物，含有该化合物的组合物，以及治疗FAK和ALK表达的疾病的方法。 疾病是例如癌症。

公开(公告)号：WO2012045196A1

公开(公告)日：2012-04-12

申请号：PCT/CN2010/001579

申请日：2010-10-09

Applicant: ABBOTT LABORATORIES ,  ABBOTT LABORATORIES TRADING (SHANGHAI) COMPANY, LTD. ,  XU, Xiangdong ,  DINGES, Jurgent ,  HASVOLD, Lisa ,  LONGENECKER, Kenton, L.

Inventor： XU, Xiangdong ,  DINGES, Jurgent ,  HASVOLD, Lisa ,  LONGENECKER, Kenton, L.

IPC: C07D241/44 ,  A61K31/498 ,  A61P35/00

CPC classification number: C07D241/44 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D413/04

Abstract: Disclosed are compounds of formula (I) or pharmaceutical acceptable salts thereof, wherein R 1 , R 2 , R 3 and R 4 are as defined in the description. Disclosed are also the methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as phosphoglycerate kinase.

Abstract translation: 公开了式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4如说明书中所定义。 还公开了制备所述化合物的方法，以及含有可用于抑制磷酸甘油酸激酶等激酶的所述化合物的组合物。

公开(公告)号：WO2007095603A2

公开(公告)日：2007-08-23

申请号：PCT/US2007/062181

申请日：2007-02-15

Applicant: ABBOTT LABORATORIES ,  GU, Yu Gui ,  XU, Xiangdong ,  WEITZBERG, Moshe ,  SHAM, Hing

Inventor： GU, Yu Gui ,  XU, Xiangdong ,  WEITZBERG, Moshe ,  SHAM, Hing

CPC classification number: C07D277/34 ,  C07D417/04

Abstract: The present invention relates to compounds of Formula (I), which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.

Abstract translation: 本发明涉及抑制乙酰辅酶A羧化酶（ACC）并可用于预防或治疗人类代谢综合征，II型糖尿病，肥胖症，动脉粥样硬化和心血管疾病的式（I）化合物。

公开(公告)号：WO2007095602A2

公开(公告)日：2007-08-23

申请号：PCT/US2007/062180

申请日：2007-02-15

Applicant: ABBOTT LABORATORIES ,  GU, Yu Gui ,  WEITZBERG, Moshe ,  XU, Xiangdong ,  CLARK, Richard, F. ,  ZHANG, Tianyuan ,  LI, Qun ,  HANSEN, Todd, M. ,  SHAM, Hing ,  BEUTEL, Bruce, A. ,  CAMP, Heidi, S. ,  WANG, Xiaojun

Inventor： GU, Yu Gui ,  WEITZBERG, Moshe ,  XU, Xiangdong ,  CLARK, Richard, F. ,  ZHANG, Tianyuan ,  LI, Qun ,  HANSEN, Todd, M. ,  SHAM, Hing ,  BEUTEL, Bruce, A. ,  CAMP, Heidi, S. ,  WANG, Xiaojun

CPC classification number: C07D277/34 ,  C07D261/08 ,  C07D277/56 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention relates to compounds of Formula (I), which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.

Abstract translation: 本发明涉及抑制乙酰辅酶A羧化酶（ACC）并可用于预防或治疗代谢综合征，II型糖尿病，肥胖症，动脉粥样硬化和心血管疾病的式（I）化合物 人类疾病。

公开(公告)号：EP1999119A2

公开(公告)日：2008-12-10

申请号：EP07757026.5

申请日：2007-02-15

Applicant: ABBOTT LABORATORIES

Inventor： GU, Yu Gui ,  WEITZBERG, Moshe ,  XU, Xiangdong ,  CLARK, Richard, F. ,  ZHANG, Tianyuan ,  LI, Qun ,  HANSEN, Todd, M. ,  SHAM, Hing ,  BEUTEL, Bruce, A. ,  CAMP, Heidi, S. ,  WANG, Xiaojun

IPC: C07D277/34 ,  A61K31/427 ,  C07D261/08 ,  C07D277/56 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

CPC classification number: C07D277/34 ,  C07D261/08 ,  C07D277/56 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention relates to compounds of formula (I), wherein R1 is selected from the group consisting of hydrogen, cycloalkyl, alkyl and haloalkyl; Y is selected from the group consisting of -(CR4aR-4b)m-, -C(O)-, -O-, -N(H)-, -N(alkyl)- and -S-; wherein m is 1, 2 or 3; Ar3 is phenyl or monocyclic heteroaryl; wherein Ar3 is substituted with 1, 2 or 3 or 4 substituents. Ar1 is selected from the group consisting of phenyl and a monocyclic, five or six- membered heteroaryl; Ar2 is a monocyclic five membered heteroaryl, wherein each Ar2 is independently unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of alkyl, alkenyl, halogen, -CN, -NO2, hydroxy, alkoxy, -NH2, -N(H)(alkyl), -N(alkyl)2. -C(O)OH, -C(O)Oalkyl, -C(O)H, -C(O)alkyl, and haloalkyl; Z is selected from the group consisting of -OR9a, -alkylenyl-OR9a, -NR6R99b; and -alkylenyl-NR6R9b; which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type U diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.

公开(公告)号：EP1991536A2

公开(公告)日：2008-11-19

申请号：EP07757027.3

申请日：2007-02-15

Applicant: ABBOTT LABORATORIES

Inventor： GU, Yu Gui ,  XU, Xiangdong ,  WEITZBERG, Moshe ,  SHAM, Hing

IPC: C07D277/34 ,  C07D417/04 ,  A61K31/426 ,  A61K31/427

CPC classification number: C07D277/34 ,  C07D417/04

Abstract: The present invention is directed to compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or combination thereof, wherein Y is selected from the group consisting of-CRxRy-, -C(O)-, -O-, -N(H)-, -N(alkyl)- and -S-; wherein each of Rx and Ry is independently selected from the group consisting of hydrogen. alkyl, hydroxyalkyl, and haloalkyl; or Rx and Ry together with the carbon to which they are attached form a monocyclic cycloalkyl or heterocycle ring, Ar1 is selected from the group consisting of phenyl and a monocyclic, five or six- membered heteroaryl, Ar3 is phenyl or monocyclic heteroaryl, wherein Ar3 is substituted with 1, 2, 3 or 4 substituents Ar2 is a group of formula (a), (b), (c), (d), or (e); wherein R is hydrogen, cycloalkyj, alkyl or haloalkyl, Z1, Z2, Z3 and Z4 are C(R101), or one or two of Z1, Z2, Z3 and Z4 is N and the others are C(R101); Z5, Z6 and Z7 are C(102). or one or two of Z5, Z6 and Z7 are N, and the others are C(R102), Z is selected from the group consisting of -OR5, -alkylenyl-OR5, -N(R6)(R7) and -alkylenyI-N(R6)(R7), which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.